Pilar Garin‐Chesa

11.9k total citations · 3 hit papers
100 papers, 9.2k citations indexed

About

Pilar Garin‐Chesa is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Pilar Garin‐Chesa has authored 100 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 44 papers in Molecular Biology and 18 papers in Cancer Research. Recurrent topics in Pilar Garin‐Chesa's work include Peptidase Inhibition and Analysis (28 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Protease and Inhibitor Mechanisms (13 papers). Pilar Garin‐Chesa is often cited by papers focused on Peptidase Inhibition and Analysis (28 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Protease and Inhibitor Mechanisms (13 papers). Pilar Garin‐Chesa collaborates with scholars based in United States, Austria and Germany. Pilar Garin‐Chesa's co-authors include Wolfgang J. Rettig, Lloyd J. Old, Jens Quant, John H. Healey, Andrew G. Huvos, John E. Park, Martin Krššák, Martin Lenter, Anke Baum and Frank Hilberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Pilar Garin‐Chesa

98 papers receiving 9.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

2008 861 citations Frank Hilberg, Gerald J. Roth et al. Cancer Research profile →
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo

2007 691 citations Anke Baum, Martin Krššák et al. profile →
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

1990 604 citations Pilar Garin‐Chesa, Lloyd J. Old et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pilar Garin‐Chesa United States	48	4.7k	3.9k	1.9k	1.8k	1.1k	100	9.2k
Wolfgang J. Rettig United States	41	4.7k 1.0×	4.8k 1.2×	1.7k 0.9×	2.1k 1.1×	1.4k 1.2×	75	9.7k
Albert J. Wong United States	54	3.8k 0.8×	6.3k 1.6×	1.3k 0.7×	1.4k 0.8×	1.3k 1.2×	94	10.5k
Herbert A. Weich Germany	52	3.2k 0.7×	7.7k 2.0×	2.9k 1.5×	933 0.5×	736 0.7×	114	11.9k
Edwin Clark United States	30	2.5k 0.5×	4.1k 1.0×	1.7k 0.9×	1.1k 0.6×	1.9k 1.7×	61	8.4k
Denise Crowley United States	37	5.5k 1.2×	8.8k 2.2×	3.5k 1.9×	2.0k 1.1×	1.1k 1.0×	48	14.0k
Rosemary J. Akhurst United States	49	4.4k 0.9×	8.7k 2.2×	1.7k 0.9×	1.2k 0.7×	953 0.9×	96	12.4k
Ulla M. Wewer Denmark	58	2.6k 0.6×	6.1k 1.6×	2.3k 1.2×	539 0.3×	1.7k 1.5×	136	11.0k
Janice Nigro United States	24	4.5k 1.0×	5.8k 1.5×	3.7k 2.0×	1.0k 0.6×	585 0.5×	32	10.6k
Clare M. Isacke United Kingdom	57	2.5k 0.5×	4.9k 1.2×	1.8k 0.9×	718 0.4×	2.0k 1.8×	141	8.5k
Michelle Letarte Canada	54	1.6k 0.4×	5.0k 1.3×	1.2k 0.6×	3.2k 1.8×	726 0.7×	173	12.3k

Countries citing papers authored by Pilar Garin‐Chesa

Since Specialization

Citations

This map shows the geographic impact of Pilar Garin‐Chesa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pilar Garin‐Chesa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pilar Garin‐Chesa more than expected).

Fields of papers citing papers by Pilar Garin‐Chesa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pilar Garin‐Chesa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pilar Garin‐Chesa. The network helps show where Pilar Garin‐Chesa may publish in the future.

Co-authorship network of co-authors of Pilar Garin‐Chesa

This figure shows the co-authorship network connecting the top 25 collaborators of Pilar Garin‐Chesa. A scholar is included among the top collaborators of Pilar Garin‐Chesa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pilar Garin‐Chesa. Pilar Garin‐Chesa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Sanderson, Michael P., Marco H. Hofmann, Pilar Garin‐Chesa, et al.. (2017). The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy. Molecular Cancer Therapeutics. 16(10). 2223–2233. 22 indexed citations

2.

Waizenegger, Irene C., Anke Baum, Steffen Steurer, et al.. (2016). A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation. Molecular Cancer Therapeutics. 15(3). 354–365. 68 indexed citations

3.

Sini, Patrizia, Ulrich Gürtler, Stephan K. Zahn, et al.. (2016). Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases. Molecular Cancer Therapeutics. 15(10). 2388–2398. 28 indexed citations

4.

Sanderson, Michael P., Joshua F. Apgar, Pilar Garin‐Chesa, et al.. (2015). BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis. Molecular Cancer Therapeutics. 14(12). 2762–2772. 16 indexed citations

5.

Rupp, Christian, Martin Scherzer, Albin Rudisch, et al.. (2014). IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor–stroma interaction. Oncogene. 34(7). 815–825. 96 indexed citations

6.

Bug, Gesine, Carsten Müller‐Tidow, Richard F. Schlenk, et al.. (2011). Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML. Blood. 118(21). 1549–1549. 13 indexed citations

7.

Hilberg, Frank, Gerald J. Roth, Martin Krššák, et al.. (2008). BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy. Cancer Research. 68(12). 4774–4782. 861 indexed citations breakdown →

8.

Baum, Anke, Pilar Garin‐Chesa, Ulrich Gürtler, Gerd Munzert, & Dorothea Rudolph. (2007). PD2-1-1: Efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in models of human non-small cell lung carcinoma. Journal of Thoracic Oncology. 2(8). S435–S436. 4 indexed citations

9.

Rupp, Christian, Helmut Dolznig, Christina Puri, et al.. (2006). Laser Capture Microdissection of Epithelial Cancers Guided by Antibodies Against Fibroblast Activation Protein and Endosialin. Diagnostic Molecular Pathology. 15(1). 35–42. 28 indexed citations

10.

Dolznig, Helmut, Norbert Schweifer, Christina Puri, et al.. (2005). Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin.. PubMed. 5. 10–10. 123 indexed citations

11.

Lee, Fook-Thean, Pilar Garin‐Chesa, John E. Park, et al.. (2003). Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.. PubMed. 2(8). 729–37. 28 indexed citations

12.

Pascolo, Emanuelle, Christian Wenz, Joachim Lingner, et al.. (2002). Mechanism of Human Telomerase Inhibition by BIBR1532, a Synthetic, Non-nucleosidic Drug Candidate. Journal of Biological Chemistry. 277(18). 15566–15572. 236 indexed citations

13.

Garin‐Chesa, Pilar, et al.. (2001). Expression of the fibroblast activation protein during mouse embryo development. The International Journal of Developmental Biology. 45(2). 445–447. 74 indexed citations

14.

Schmidt, Alexej, Jörg F. Rippmann, Bodo Brocks, et al.. (2001). Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas. International Journal of Cancer. 92(2). 240–248. 1 indexed citations

15.

Tanswell, P., Pilar Garin‐Chesa, Wolfgang J. Rettig, et al.. (2001). Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. British Journal of Clinical Pharmacology. 51(2). 177–180. 1 indexed citations

16.

Tanswell, P., Pilar Garin‐Chesa, Wolfgang J. Rettig, et al.. (2001). Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. British Journal of Clinical Pharmacology. 51(2). 177–180. 37 indexed citations

17.

Mathew, S, Matthew J. Scanlan, B.K. Mohan Raj, et al.. (1995). The gene for fibroblast activation protein α (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics. 25(1). 335–337. 62 indexed citations

18.

Yoshikawa, Hideki, Kunio Takaoka, Edward M. Alderman, et al.. (1994). Expression of bone morphogenetic proteins in human osteosarcoma. Immunohistochemical detection with monoclonal antibody. Cancer. 73(1). 85–91. 65 indexed citations

19.

Rettig, Wolfgang J., Pilar Garin‐Chesa, John H. Healey, et al.. (1993). Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.. PubMed. 53(14). 3327–35. 161 indexed citations

20.

Garin‐Chesa, Pilar, Lloyd J. Old, & Wolfgang J. Rettig. (1990). Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.. Proceedings of the National Academy of Sciences. 87(18). 7235–7239. 604 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact